Serum Institute of India-Manufactured Ebola Vaccine Enters Clinical Trial in Uganda
The Pune-based Serum Institute has manufactured and stockpiled approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate within two weeks, demonstrating its ability to rapidly scale production during an infectious disease emergency. The company also supplied around 3,000 investigational doses for the Ugandan clinical trial.